MedTrace Logo

Nano MRI on 7 Tesla in Rectal and Breast Cancer

NCT02751606 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-12-06

No results posted yet for this study

Summary

This study evaluates the diagnostic accuracy of an USPIO contrast agent (ferumoxtran-10) in combination with 7 Tesla MRI to detect lymph node metastases in rectal and breast cancer.

Conditions

  • Rectal Neoplasms
  • Breast Neoplasms

Interventions

DRUG

ferumoxtran-10

ferumoxtran-10 will be administered intravenously one day prior to the MRI scan

DEVICE

7 Tesla MRI

Subjects undergo a 7 Tesla MRI scan

DEVICE

3 Tesla MRI

Subjects undergo a 3 Tesla MRI scan

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Tom Scheenen, PhD · Radboudumc Nijmegen

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2019-06-30
Completion
2019-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02751606 on ClinicalTrials.gov